Cellectar Biosc (CLRB)

$0.29 -0.07 (-20.16%)
Market Cap 16.84M
Revenue (ttm) 0.00
Net Income (ttm) -44.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,765,327
Avg Vol 14,877,256
Day's Range N/A - N/A
Shares Out 46.08M
Stochastic %K 31%
Beta 0.52
Analysts Sell
Price Target $4.00

Company Profile

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort,...

Industry: Biotechnology
Sector: Healthcare
Phone: 608 441 8120
Address:
100 Campus Drive, Florham Park, United States
dang1976
dang1976 Jul. 7 at 9:51 PM
$CLRB, insiders bought shares on 3rd of July.
0 · Reply
EvenBetter99
EvenBetter99 Jul. 7 at 7:42 PM
$CLRB Has a top cancer targeting Technology - soon it will be on the market for WM. PDC technology best in class - safe, effective, easy to use. 🚀🚀🚀🚀🚀
0 · Reply
Slab6
Slab6 Jul. 7 at 5:27 PM
$CLRB can it go lower? Please? Seems like it’s stuck here
0 · Reply
RadioIsotope25
RadioIsotope25 Jul. 7 at 2:15 PM
$CLRB Much more upside in Radiopharm Theranostics and lower share price. Lantheus bought $5 million worth at $11.70…
0 · Reply
kalbany
kalbany Jul. 7 at 2:07 PM
$CLRB Now I know why people don't trust this company to make the right decision. My stake is very small, so I don't feel bad. I understand why folks don't jump in either.
1 · Reply
Heywood_Jablomi
Heywood_Jablomi Jul. 7 at 1:52 PM
$CLRB well, people clearly aren’t buying the dip here
1 · Reply
EvenBetter99
EvenBetter99 Jul. 6 at 7:51 AM
$CLRB 1 Billion Mct Cap will multiply the share price about 115 times.
0 · Reply
YasirTrades
YasirTrades Jul. 5 at 3:26 AM
GLMD is running out of time in a good way. The 90-day definitive agreement window from April 28th ends this month. You don’t get many biotech plays under $1 with a $12+ book value and real M&A potential. Low float, strong cash, and a clear catalyst. It’s a ticking time bomb in a setup kind of way. $CABA $ALLR $CNTB $CLRB
0 · Reply
Scorpole
Scorpole Jul. 3 at 4:45 PM
$CLRB So that was the purpose with R/S and offering. Just so the management could get cheaper shares
2 · Reply
szcyxzh
szcyxzh Jul. 3 at 4:09 PM
$CLRB Reminder: CEO James Caruso’s total comp in 2023 was over $1 million, including cash salary and stock awards. Other executives received similarly high compensation relative to company revenue (which is $0). They contributed a symbolic amount during dilution, while drawing six- or seven-figure salaries funded by those very dilution rounds. Draw your own conclusion.
0 · Reply
Latest News on CLRB
Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option

Jul 2, 2025, 4:15 PM EDT - 5 days ago

Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option

Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering

Jul 1, 2025, 9:25 AM EDT - 6 days ago

Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering

Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

Jun 26, 2025, 8:05 AM EDT - 11 days ago

Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)

Jun 24, 2025, 8:30 AM EDT - 13 days ago

Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)

Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split

Jun 18, 2025, 4:30 PM EDT - 19 days ago

Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split

Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma

Jun 11, 2025, 8:05 AM EDT - 26 days ago

Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma

Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules

Jun 5, 2025, 9:00 AM EDT - 4 weeks ago

Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules

Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)

Jun 4, 2025, 8:05 AM EDT - 4 weeks ago

Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)

Cellectar Biosciences Inc. (CLRB) Q1 2025 Earnings Call Transcript

May 13, 2025, 2:17 PM EDT - 7 weeks ago

Cellectar Biosciences Inc. (CLRB) Q1 2025 Earnings Call Transcript

Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

May 13, 2025, 7:05 AM EDT - 7 weeks ago

Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025

May 7, 2025, 8:05 AM EDT - 2 months ago

Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025

Cellectar Announces Plan to Explore Strategic Alternatives

Apr 30, 2025, 8:05 AM EDT - 2 months ago

Cellectar Announces Plan to Explore Strategic Alternatives

Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 12:41 PM EDT - 4 months ago

Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call Transcript

Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update

Mar 13, 2025, 7:05 AM EDT - 4 months ago

Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update

Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025

Mar 5, 2025, 8:05 AM EST - 4 months ago

Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025

Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 8:05 AM EST - 5 months ago

Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference

Jan 12, 2025, 6:00 PM EST - 6 months ago

Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference

Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options

Dec 11, 2024, 11:25 AM EST - 7 months ago

Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options

Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring

Dec 10, 2024, 5:00 PM EST - 7 months ago

Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring

NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)

Nov 21, 2024, 8:00 AM EST - 8 months ago

NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)

Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript

Nov 18, 2024, 10:59 AM EST - 8 months ago

Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript

Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update

Nov 18, 2024, 7:05 AM EST - 8 months ago

Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update

Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225

Nov 14, 2024, 8:05 AM EST - 8 months ago

Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225

Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer

Nov 12, 2024, 8:05 AM EST - 8 months ago

Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024

Nov 11, 2024, 4:05 PM EST - 8 months ago

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024

Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024

Nov 7, 2024, 6:40 AM EST - 8 months ago

Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024

Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q

Nov 1, 2024, 5:00 PM EDT - 8 months ago

Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q

Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's Macroglobulinemia

Aug 26, 2024, 6:40 AM EDT - 11 months ago

Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's Macroglobulinemia

Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq

Aug 23, 2024, 5:00 PM EDT - 11 months ago

Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq

Cellectar Biosciences, Inc. (CLRB) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 1:25 PM EDT - 11 months ago

Cellectar Biosciences, Inc. (CLRB) Q2 2024 Earnings Call Transcript

Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update

Aug 13, 2024, 6:40 AM EDT - 11 months ago

Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update

UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024

Aug 8, 2024, 5:15 PM EDT - 11 months ago

UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024

Cellectar Biosciences, Inc. (CLRB) KOL and Analyst Day Call Transcript

Jul 24, 2024, 3:22 PM EDT - 1 year ago

Cellectar Biosciences, Inc. (CLRB) KOL and Analyst Day Call Transcript

Cellectar: WM Treatment Data Leads To A Few Regulatory Milestones

Jul 23, 2024, 3:09 PM EDT - 1 year ago

Cellectar: WM Treatment Data Leads To A Few Regulatory Milestones

Cancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer Study

Jul 23, 2024, 10:49 AM EDT - 1 year ago

Cancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer Study

Cellectar Biosciences' Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom's Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months

Jul 23, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences' Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom's Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months

Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million

Jul 22, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million

Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom's Macroglobulinemia Market Landscape

Jun 27, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom's Macroglobulinemia Market Landscape

Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides

May 29, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides

Cellectar Biosciences: Still Working On That Hit (Maintain Buy)

May 20, 2024, 1:02 PM EDT - 1 year ago

Cellectar Biosciences: Still Working On That Hit (Maintain Buy)

Cellectar Biosciences, Inc. (CLRB) Q1 2024 Earnings Call Transcript

May 14, 2024, 1:05 PM EDT - 1 year ago

Cellectar Biosciences, Inc. (CLRB) Q1 2024 Earnings Call Transcript

Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update

May 14, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update

Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day

May 8, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day

Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024

May 7, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024

Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript

Mar 27, 2024, 12:27 PM EDT - 1 year ago

Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript

Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update

Mar 27, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update

Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024

Mar 20, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024

Cellectar Biosciences to Present at the 36th Annual Roth Conference

Mar 14, 2024, 8:52 AM EDT - 1 year ago

Cellectar Biosciences to Present at the 36th Annual Roth Conference

Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer

Mar 4, 2024, 6:40 AM EST - 1 year ago

Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer

Cellectar Biosciences: A Shoestring Opportunity You're About To Miss

Feb 12, 2024, 1:34 AM EST - 1 year ago

Cellectar Biosciences: A Shoestring Opportunity You're About To Miss

dang1976
dang1976 Jul. 7 at 9:51 PM
$CLRB, insiders bought shares on 3rd of July.
0 · Reply
EvenBetter99
EvenBetter99 Jul. 7 at 7:42 PM
$CLRB Has a top cancer targeting Technology - soon it will be on the market for WM. PDC technology best in class - safe, effective, easy to use. 🚀🚀🚀🚀🚀
0 · Reply
Slab6
Slab6 Jul. 7 at 5:27 PM
$CLRB can it go lower? Please? Seems like it’s stuck here
0 · Reply
RadioIsotope25
RadioIsotope25 Jul. 7 at 2:15 PM
$CLRB Much more upside in Radiopharm Theranostics and lower share price. Lantheus bought $5 million worth at $11.70…
0 · Reply
kalbany
kalbany Jul. 7 at 2:07 PM
$CLRB Now I know why people don't trust this company to make the right decision. My stake is very small, so I don't feel bad. I understand why folks don't jump in either.
1 · Reply
Heywood_Jablomi
Heywood_Jablomi Jul. 7 at 1:52 PM
$CLRB well, people clearly aren’t buying the dip here
1 · Reply
EvenBetter99
EvenBetter99 Jul. 6 at 7:51 AM
$CLRB 1 Billion Mct Cap will multiply the share price about 115 times.
0 · Reply
YasirTrades
YasirTrades Jul. 5 at 3:26 AM
GLMD is running out of time in a good way. The 90-day definitive agreement window from April 28th ends this month. You don’t get many biotech plays under $1 with a $12+ book value and real M&A potential. Low float, strong cash, and a clear catalyst. It’s a ticking time bomb in a setup kind of way. $CABA $ALLR $CNTB $CLRB
0 · Reply
Scorpole
Scorpole Jul. 3 at 4:45 PM
$CLRB So that was the purpose with R/S and offering. Just so the management could get cheaper shares
2 · Reply
szcyxzh
szcyxzh Jul. 3 at 4:09 PM
$CLRB Reminder: CEO James Caruso’s total comp in 2023 was over $1 million, including cash salary and stock awards. Other executives received similarly high compensation relative to company revenue (which is $0). They contributed a symbolic amount during dilution, while drawing six- or seven-figure salaries funded by those very dilution rounds. Draw your own conclusion.
0 · Reply
GeneralVonEssen
GeneralVonEssen Jul. 3 at 3:37 PM
$CLRB wow offering of $4 on public shares? What did they think wpuld happen?
1 · Reply
szcyxzh
szcyxzh Jul. 3 at 3:04 PM
$CLRB The management pay out 50,000 to show supports (crocodile tears), then draws a million dollar paycheck from the raising as a result of the dilution. It is a good business if you can find one.
0 · Reply
Slab6
Slab6 Jul. 3 at 2:45 PM
$CLRB did the short interest really decrease by 95%??
0 · Reply
Pedelco
Pedelco Jul. 3 at 2:43 PM
$CLRB do it like James 💰 and buy
0 · Reply
Slab6
Slab6 Jul. 3 at 2:42 PM
$CLRB market cap of 9 million 😂
0 · Reply
Slab6
Slab6 Jul. 3 at 2:05 PM
$CLRB CEO, CFO, and COO bought at $4.99. Scooped a few here. Looks like price is going to stabilize here moving forward hopefully! 🤞🏻
1 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Jul. 3 at 2:05 PM
$CLRB CEO purchased 10,000 shares at $4.99 for a total of $49,900. CARUSO JAMES V now owns 11,638 shares. https://ceo-buys.com
0 · Reply
Slab6
Slab6 Jul. 3 at 1:39 PM
$CLRB looks like insiders are loading up
1 · Reply
RAGC
RAGC Jul. 3 at 1:17 PM
$CLRB news 👇
1 · Reply
szcyxzh
szcyxzh Jul. 2 at 11:35 PM
$CLRB and the 6-month runway extension is based on assumption that they can timely enroll eligible patients. TRBC is hard to find. And the track record for previous trials from this management is disaster, to put it politely.
1 · Reply
szcyxzh
szcyxzh Jul. 2 at 11:25 PM
$CLRB quarterly burn rate is around $3–4 million, management pay is over 2 million annually. This 150% dilution buys shareholders another 6 months from today at most.
0 · Reply
szcyxzh
szcyxzh Jul. 2 at 11:12 PM
$CLRB What the management will repeat is that: announce positive trial news, draw ppt for a few academic conferences, then say regulation challenges and need more money to run this show, until retirement. no product, no revenue, no honor of words but only care about their paycheck.
0 · Reply